Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021

Authors

  • Anna L.V. Johansson Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  • Simon M. Kønig Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark
  • Siri Larønningen Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway
  • Gerda Engholm Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark
  • Niels Kroman Department Breast Surgery, Copenhagen University Hospital (Herlev/Gentofte), Copenhagen, Denmark
  • Karri Seppä Finnish Cancer Registry, Helsinki, Finland; Faculty of Social Sciences, Tampere University, Tampere, Finland
  • Nea Malila Finnish Cancer Registry, Helsinki, Finland
  • Bjarni Á. Steig National Hospital of the Faroe Islands, Tórshavn, Faroe Islands
  • Eva Maria Gudmundsdóttir Icelandic Cancer Registry, Reykjavík, Iceland
  • Elínborg J. Ólafsdóttir Icelandic Cancer Registry, Reykjavík, Iceland
  • Frida E. Lundberg Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Therese M.-L. Andersson Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  • Paul C. Lambert Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Biostatistics Research Group, Department of Health Sciences, University of Leicester, UK
  • Mats Lambe Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Regional Cancer Center Mid-Sweden, Uppsala, Sweden
  • David Pettersson Swedish Cancer Registry, National Board of Health and Welfare, Stockholm, Sweden
  • Bjarte Aagnes Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway
  • Søren Friis Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark
  • Hans Storm Danish Cancer Society, Copenhagen, Denmark

DOI:

https://doi.org/10.2340/1651-226X.2024.35094

Keywords:

Cancer survival, Epidemiology, Denmark, Finland, Iceland, Norway, Sweden

Abstract

Background: Since the early 2000s, overall and site-specific cancer survival have improved substantially in the Nordic countries. We evaluated whether the improvements have been similar across countries, major cancer types, and age groups.

Material and methods: Using population-based data from the five Nordic cancer registries recorded in the NORDCAN database, we included a cohort of 1,525,854 men and 1,378,470 women diagnosed with cancer (except non-melanoma skin cancer) during 2002–2021, and followed for death until 2021. We estimated 5-year relative survival (RS) in 5-year calendar periods, and percentage points (pp) differences in 5-year RS from 2002–2006 until 2017–2021. Separate analyses were performed for eight cancer sites (i.e. colorectum, pancreas, lung, breast, cervix uteri, kidney, prostate, and melanoma of skin).

Results: Five-year RS improved across nearly all cancer sites in all countries (except Iceland), with absolute differences across age groups ranging from 1 to 21 pp (all cancer sites), 2 to 20 pp (colorectum), -1 to 36 pp (pancreas), 2 to 28 pp (lung), 0 to 9 pp (breast), -11 to 26 pp (cervix uteri), 2 to 44 pp (kidney), -2 to 23 pp (prostate) and -3 to 30 pp (skin melanoma). The oldest patients (80–89 years) exhibited lower survival across all countries and sites, although with varying improvements over time.

Interpretation: Nordic cancer patients have generally experienced substantial improvements in cancer survival during the last two decades, including major cancer sites and age groups. Although survival has improved over time, older patients remain at a lower cancer survival compared to younger patients.

Downloads

Download data is not yet available.

References

Lundberg FE, Andersson TM-L, Lambe M, et al. Trends in cancer survival in the Nordic countries 1990–2016: the NORDCAN survival studies. Acta Oncol. 2020;59:1266–74.

https://doi.org/10.1080/0284186X.2020.1822544 DOI: https://doi.org/10.1080/0284186X.2020.1822544

Lundberg FE, Birgisson H, Johannesen TB, et al. Survival trends in patients diagnosed with colon and rectal cancer in the Nordic countries 1990–2016: The NORDCAN survival studies. Eur J Cancer. 2022;172:76–84.

https://doi.org/10.1016/j.ejca.2022.05.032 DOI: https://doi.org/10.1016/j.ejca.2022.05.032

Lundberg FE, Kroman N, Lambe M, et al. Age-specific survival trends and life-years lost in women with breast cancer 1990–2016: the NORDCAN survival studies. Acta Oncol. 2022;61:1481–9.

https://doi.org/10.1080/0284186X.2022.2156811 DOI: https://doi.org/10.1080/0284186X.2022.2156811

Storm HH, Engholm G, Hakulinen T, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999–2003 followed to the end of 2006. A critical overview of the results. Acta Oncol. 2010;49:532–44.

https://doi.org/10.3109/02841861003801148 DOI: https://doi.org/10.3109/02841861003801148

Engholm G, Gislum M, Bray F, Hakulinen T. Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Material and methods. Acta Oncol. 2010;49:545–60.

https://doi.org/10.3109/02841861003739322 DOI: https://doi.org/10.3109/02841861003739322

Hakulinen T, Tryggvadóttir L, Gislum M, et al. Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:561–77.

https://doi.org/10.3109/02841860903575307 DOI: https://doi.org/10.3109/02841860903575307

Klint Å, Engholm G, Storm HH, et al. Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:578–607.

https://doi.org/10.3109/02841861003739330 DOI: https://doi.org/10.3109/02841861003739330

Hakulinen T, Engholm G, Gislum M, et al. Trends in the survival of patients diagnosed with cancers in the respiratory system in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:608–23.

https://doi.org/10.3109/02841860903575281 DOI: https://doi.org/10.3109/02841860903575281

Tryggvadóttir L, Gislum M, Bray F, et al. Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:624–31.

https://doi.org/10.3109/02841860903575323 DOI: https://doi.org/10.3109/02841860903575323

Klint Å, Engholm G, Storm HH, et al. Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic coun-tries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:632–43.

https://doi.org/10.3109/02841861003691945 DOI: https://doi.org/10.3109/02841861003691945

Bray F, Klint Å, Gislum M, et al. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol. 2010;49:644–54.

https://doi.org/10.3109/02841860903575315 DOI: https://doi.org/10.3109/02841860903575315

Engholm G, Hakulinen T, Gislum M, et al. Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:655–64.

https://doi.org/10.3109/02841860903575299 DOI: https://doi.org/10.3109/02841860903575299

Tryggvadóttir L, Gislum M, Hakulinen T, et al. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:665–72.

https://doi.org/10.3109/02841861003702528 DOI: https://doi.org/10.3109/02841861003702528

Bray F, Engholm G, Hakulinen T, et al. Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964–2003 followed up until the end of 2006. Acta Oncol. 2010;49:673–93.

https://doi.org/10.3109/02841861003610200

Storm HH, Klint Å, Tryggvadóttir L, et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoi-etic, and related tissue in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:694–712. DOI: https://doi.org/10.3109/02841861003631495

https://doi.org/10.3109/02841861003610200 DOI: https://doi.org/10.3109/02841861003610200

Engholm G, Ferlay J, Christensen N, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49:725–36.

https://doi.org/10.3109/02841861003782017 DOI: https://doi.org/10.3109/02841861003782017

Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians – a national Danish project. Health Policy. 2012;105:65–70.

https://doi.org/10.1016/j.healthpol.2011.11.001 DOI: https://doi.org/10.1016/j.healthpol.2011.11.001

Schmidt I, Thor J, Davidson T, Nilsson F, Carlsson C. The national program on standardized cancer care pathways in Sweden: observations and findings half way through. Health Policy. 2018;122:945–8.

https://doi.org/10.1016/j.healthpol.2018.07.012 DOI: https://doi.org/10.1016/j.healthpol.2018.07.012

Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Møller B. Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015–2016. BMC Cancer. 2020;20:488.

https://doi.org/10.1186/s12885-020-06979-y DOI: https://doi.org/10.1186/s12885-020-06979-y

Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treat-ment (Review). Int J Oncol. 2018;54:407–19.

https://doi.org/10.3892/ijo.2018.4661 DOI: https://doi.org/10.3892/ijo.2018.4661

Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol. 2015;12:115–24.

https://doi.org/10.1038/nrclinonc.2014.191 DOI: https://doi.org/10.1038/nrclinonc.2014.191

Andersson TM-L, Myklebust TÅ, Rutherford MJ, et al. Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2. Br J Cancer. 2022;126:1224.

https://doi.org/10.1038/s41416-022-01701-0 DOI: https://doi.org/10.1038/s41416-022-01701-0

Larønningen S, Arvidsson G, Bray F, et al. NORDCAN: Cancer incidence, mortality, prevalence and survival in the Nordic countries, version 9.3 (02.10.2023). Association of the Nordic Cancer Registries. Cancer Registry of Norway; Oslo, 2023.

Pukkala E, Engholm G, Højsgaard Schmidt LK, et al. Nordic Cancer Registries – an overview of their procedures and data comparability. Acta Oncol. 2018;57:440–55.

https://doi.org/10.1080/0284186X.2017.1407039 DOI: https://doi.org/10.1080/0284186X.2017.1407039

Association of Nordic Cancer Registries. NORDCAN: Cancer incidence and mortality in the Nordic countries. Years 1973–98. Version 1.0. Electronic Publication. Copenhagen: Danish Cancer Society; 2002.

Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and Conversion Programs for Cancer Registries (IARC/IACR Tools for Cancer Registries). Lyon: International Agency for Research on Cancer; 2005.

Pohar Perme M, Stare J, Estève J. On estimation in relative survival. Biometrics. 2012;68:113–20.

https://doi.org/10.1111/j.1541-0420.2011.01640.x DOI: https://doi.org/10.1111/j.1541-0420.2011.01640.x

Coviello E, Seppä K, Dickman PW, Pokhrel A. Estimating net survival using a life-table approach. The Stata J. 2015;15:173–85.

https://doi.org/10.1177/1536867X1501500111 DOI: https://doi.org/10.1177/1536867X1501500111

O’Sullivan JW, Muntinga T, Grigg S, Ioannidis JPA. Prevalence and outcomes of incidental imaging findings: umbrella review. Br Med J. 2018;361:k2387.

https://doi.org/10.1136/bmj.k2387 DOI: https://doi.org/10.1136/bmj.k2387

Ejlertsen B, Offersen BV, Overgaard J, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2017;57:3–12.

https://doi.org/10.1080/0284186X.2017.1408962 DOI: https://doi.org/10.1080/0284186X.2017.1408962

Stormark K, Søreide K, Søreide JA, et al. Nationwide implementation of laparoscopic surgery for colon cancer: short-term outcomes and long-term survival in a population-based cohort. Surg Endosc. 2016;30:4853–64.

https://doi.org/10.1007/s00464-016-4819-8 DOI: https://doi.org/10.1007/s00464-016-4819-8

Åsli LM, Johannesen TB, Myklebust TÅ, Møller B, Eriksen MT, Guren MG. Preoperative chemoradiotherapy for rectal cancer and impact on outcomes – a population-based study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;123:446–53.

https://doi.org/10.1016/j.radonc.2017.04.012 DOI: https://doi.org/10.1016/j.radonc.2017.04.012

Dingemans A-MC, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:839.

https://doi.org/10.1016/j.annonc.2021.03.207 DOI: https://doi.org/10.1016/j.annonc.2021.03.207

Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up††Approved by the ESMO Guidelines Committee: February 2002, last update September 2019. Ann Oncol. 2019;30:1884–901.

https://doi.org/10.1093/annonc/mdz411 DOI: https://doi.org/10.1093/annonc/mdz411

Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111:965–9.

https://doi.org/10.1038/bjc.2014.362 DOI: https://doi.org/10.1038/bjc.2014.362

Lindebjerg J, Osler M, Bisgaard C. Colorectal cancers detected through screening are associated with lower stages and improved survival. Danish Med J. 2014;61:A4758.

Linnansaari A, Ollila H, Pisinger C, Scheffels J, Kinnunen JM, Rimpelä A. Towards tobacco-free generation: implementation of preventive tobacco policies in the Nordic countries. Rev Scand J Public Health. 2023;51:1108–21.

https://doi.org/10.1177/14034948221106867 DOI: https://doi.org/10.1177/14034948221106867

Christensen NL, Jekunen A, Heinonen S, Dalton SO, Rasmussen TR. Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncol. 2017;56:943–8.

https://doi.org/10.1080/0284186X.2017.1315172 DOI: https://doi.org/10.1080/0284186X.2017.1315172

Baban CK, Devane L, Geraghty J. Change of paradigm in treating elderly with breast cancer: are we undertreating elderly patients? Irish J Med Sci. 2019;188:379–88.

https://doi.org/10.1007/s11845-018-1851-9 DOI: https://doi.org/10.1007/s11845-018-1851-9

Araghi M, Arnold M, Rutherford MJ, et al. Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut. 2021;70:114–26.

https://doi.org/10.1136/gutjnl-2020-320625 DOI: https://doi.org/10.1136/gutjnl-2020-320625

Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.

https://doi.org/10.1016/S0140-6736(17)33326-3 DOI: https://doi.org/10.1016/S0140-6736(17)33326-3

De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol. 2014;15:23–34.

https://doi.org/10.1016/S1470-2045(13)70546-1 DOI: https://doi.org/10.1016/S1470-2045(13)70546-1

Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–505.

https://doi.org/10.1016/S1470-2045(19)30456-5 DOI: https://doi.org/10.1016/S1470-2045(19)30456-5

Cabasag CJ, Arnold M, Piñeros M, et al. Population-based cancer staging for oesophageal, gastric, and pancreatic cancer 2012–2014: Inter-national Cancer Benchmarking Partnership SurvMark-2. Int J Cancer. 2021;149:1239–46.

https://doi.org/10.1002/ijc.33679 DOI: https://doi.org/10.1002/ijc.33679

Sant M, Chirlaque Lopez MD, Agresti R, et al. Survival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EUROCARE-5 study. European Journal of Cancer. 2015;51:2191–205.

https://doi.org/10.1016/j.ejca.2015.07.022 DOI: https://doi.org/10.1016/j.ejca.2015.07.022

Pilleron S, Charvat H, Araghi M, et al. Age disparities in stage-specific colon cancer survival across seven countries: an International Cancer Benchmarking Partnership SURVMARK-2 population-based study. Int J Cancer. 2021;148:1575–85.

https://doi.org/10.1002/ijc.33326 DOI: https://doi.org/10.1002/ijc.33326

Araghi M, Fidler-Benaoudia M, Arnold M, et al. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study. Thorax. 2022;77:378–90.

https://doi.org/10.1136/thoraxjnl-2020-216555 DOI: https://doi.org/10.1136/thoraxjnl-2020-216555

Storm HH, Larønningen S, Bray F. Do investments in cancer registry databases and tools bring added value? NORDCAN as an example. Acta Oncol. 2023;62:535–40.

https://doi.org/10.1080/0284186X.2023.2218557 DOI: https://doi.org/10.1080/0284186X.2023.2218557

Lambe M, Wigertz A, Sandin F, et al. Estimates of lung and pancreatic cancer survival in Sweden with and without inclusion of death certifi-cate initiated (DCI) cases. Acta Oncol. 2020;59:1322–8.

https://doi.org/10.1080/0284186X.2020.1826572 DOI: https://doi.org/10.1080/0284186X.2020.1826572

Published

2024-04-10

How to Cite

Johansson, A. L., Kønig, S. M., Larønningen, S., Engholm, G., Kroman, N., Seppä, K., … Storm, H. (2024). Have the recent advancements in cancer therapy and survival benefitted patients of all age groups across the Nordic countries? NORDCAN survival analyses 2002-2021. Acta Oncologica, 63(1), 179–191. https://doi.org/10.2340/1651-226X.2024.35094

Issue

Section

Original article

Categories